In clinical trials, sirolimus (rapamycin, a macrocyclic lactone) has been shown to exhibit antitumor activity across a variety of human cancers by binding to and inhibiting the activation of the mammalian target of rapamycin (mTOR), thus preventing cell cycle progression from th…
"1" Result
Sort By: